Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PANCREATIC CANCER

The genomic landscape of recurrent pancreatic cancer is modified by treatment

Nature Reviews Gastroenterology & Hepatology volume 17, pages 389–390 (2020)Cite this article

Subjects

Most patients who undergo curative intent surgery for pancreatic cancer will still die of recurrent disease. A new study shows that pancreatic tumours that pass through the genetic bottlenecks of surgery and additional chemoradiotherapy have altered mutational signatures, driver genes and subclonal architecture.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Genetic alterations observed in recurrent pancreatic cancer.

References

  1. Van Roessel, S. et al. International validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in patients with resected pancreatic cancer. JAMA Surg. 153, 1–8 (2018).

    Article  Google Scholar 

  2. Connor, A. A. et al. Integration of genomic and transcriptional features in pancreatic cancer reveals increased cell cycle progression in metastases. Cancer Cell 35, 267–282 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Makohon-Moore, A. P. et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat. Genet. 49, 358–366 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Sakamoto, H. et al. The evolutionary origins of recurrent pancreatic cancer. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-19-1508 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Raphael, B. J. et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185–203 (2017).

    Article  Google Scholar 

  6. Chan-Seng-Yue, M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. 52, 231–240 (2020).

    Article  CAS  PubMed  Google Scholar 

  7. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Pleasance, E. et al. Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nat. Cancer 1, 452–468 (2020).

    Article  PubMed  Google Scholar 

  9. Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349–361 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Luchini, C. et al. Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. Mod. Pathol. 32, 659–665 (2019).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank A. A. Connor and F. Notta for their helpful comments.

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

    Irene Y. Xie

  2. PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada

    Steven Gallinger

Authors
  1. Irene Y. Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven Gallinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven Gallinger.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xie, I.Y., Gallinger, S. The genomic landscape of recurrent pancreatic cancer is modified by treatment. Nat Rev Gastroenterol Hepatol 17, 389–390 (2020). https://doi.org/10.1038/s41575-020-0321-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-020-0321-9

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer